Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported net losses of $2.3 million for the third quarter and $7.9 million for the first nine months of 2026, compared with $4.0 million and $16.5 million in the corresponding 2025 periods. It had $17.5 million in cash and cash equivalents at September 30, 2026, while operating activities used $8.1 million over nine months. The March 2026 public offering provided approximately $8.9 million in net proceeds.
The company said its current cash was insufficient for operating needs over the next 12 months, although it believed cash would cover anticipated outlays into the third quarter of 2027; it expects additional fundraising before then and disclosed substantial doubt about its ability to continue as a going concern for one year after the financial statements’ issuance. RVPH’s common stock was suspended from Nasdaq trading on May 14, 2026, and has been quoted on OTCQB since then. RECOVER-2 enrollment is planned for the first half of 2027, subject to additional financing, with study completion expected in 2028.
Reviva Pharmaceuticals Holdings, Inc. reported a third-quarter 2026 net loss of $2,298,905, compared with $4,010,773 a year earlier; total operating expenses were $2,432,518 versus $4,029,841. Cash and cash equivalents were $17,458,418 as of September 30, 2026, compared with $14,438,792 as of December 31, 2025.
Reviva expects FDA feedback in the fourth quarter of 2026 on a proposed new brilaroxazine formulation for the RECOVER-2 trial and a future NDA submission. A bioequivalence study is planned for the first quarter of 2027; RECOVER-2 enrollment is expected to begin in the first half of 2027, subject to additional financing. The U.S. patent office granted priority examination to the formulation’s composition-of-matter patent application, which could extend protection through 2046. RVPH common stock has been quoted on OTCQB since its Nasdaq suspension on May 14, 2026.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) will hold its virtual annual meeting on December 18, 2026. Stockholders will vote on five director nominees, auditor ratification, advisory executive compensation, adjournment, and an amendment that would authorize a reverse split at a ratio from 1-for-2 to 1-for-100 at any time before December 31, 2027. The Board would decide whether to implement the split and select the ratio, without further stockholder approval. The Board recommends voting “FOR” each proposal.
As of October 30, 2026, 13,110,377 common shares were outstanding. The 2025 pay-versus-performance table reports a net loss of $19,864,902, compared with $29,918,802 in 2024. The 2025 summary compensation table lists total compensation of $1,442,121 for CEO Laxminarayan Bhat and $659,670 for CFO Narayan Prabhu.
Reviva Pharmaceuticals Holdings, Inc. is asking stockholders at its December 18, 2026 annual meeting to elect five directors, ratify Baker Tilly US, LLP as auditor for 2026, approve executive pay on an advisory basis, approve a reverse-split amendment, and authorize adjournment if needed to solicit additional proxies. The proposed split ranges from one-for-two (1:2) to one-for-one hundred (1:100) and may occur any time prior to December 31, 2027. If approved, the amendment would leave the decision whether to implement the split and which ratio to use to the Board’s sole discretion, without further stockholder approval.
For 2025, total compensation was $1,442,121 for Chief Executive Officer Laxminarayan Bhat and $659,670 for Chief Financial Officer Narayan Prabhu; these totals include the grant-date fair value of option awards. The company reported a $19,864,902 net loss for 2025 and a $6.56 value for a $100 initial investment based on cumulative total shareholder return. Common shares outstanding were 13,110,377 as of September 30, 2026. The meeting is virtual, and October 30, 2026 is the voting record date.
Barclays PLC filed an amended Schedule 13G reporting its beneficial ownership in Reviva Pharmaceuticals Holdings common stock. Barclays reports beneficial ownership of 20 shares, representing 0.00% of the class as of June 30, 2026. Barclays has sole voting power and sole dispositive power over all 20 shares, with no shared voting or dispositive power. The filing confirms that Barclays’ holdings are classified as ownership of 5 percent or less of the class.
Reviva Pharmaceuticals Holdings, Inc. reported unaudited results for the quarter ended June 30, 2026. Cash and cash equivalents were $19.9 million, up from $14.4 million at December 31, 2025, and working capital surplus was $15.2 million. Total assets were $21.1 million.
The company generated no product revenue and recorded a net loss of $2.4 million for the quarter and $5.6 million for the first half of 2026, narrower than the prior-year periods, driven by sharply lower research and development expenses (down to $1.4 million from $3.7 million in the quarter) as its RECOVER-1 open-label extension study wound down, and reduced general and administrative costs.
Reviva raised capital through a March 2026 public offering, which delivered net proceeds of about $8.9 million, and an at-the-market program that added approximately $2.5 million in the first half, and it has significant warrant overhang. Management believes existing cash can fund operations into July 2027, yet explicitly states that cash on hand is not sufficient for 12 months from issuance and discloses substantial doubt about its ability to continue as a going concern without additional financing. During the period, the company completed a 1-for-20 reverse stock split and its common stock was delisted from Nasdaq and is now quoted on the OTCQB Venture Market.
Reviva Pharmaceuticals Holdings, Inc. reported second quarter 2026 results and outlined key milestones for its lead drug candidate brilaroxazine. A U.S. composition of matter patent application for a new form of brilaroxazine is seeking accelerated review, which the company believes could extend patent life and commercial exclusivity through 2046. FDA feedback on use of the new formulation in the RECOVER-2 registrational Phase 3 schizophrenia trial and in a planned New Drug Application is expected in the fourth quarter of 2026, with a bioequivalence study planned for the same period and RECOVER-2 patient enrollment targeted for the first half of 2027, subject to additional financing.
Cash and cash equivalents were $19.9 million as of June 30, 2026, up from $14.4 million at December 31, 2025, with total assets of $21.1 million and total liabilities of $5.9 million. For the quarter, operating expenses fell to $2.6 million from $6.1 million a year earlier, and net loss narrowed to $2.45 million (or $0.19 per share) from $6.05 million (or $2.40 per share). Stockholders’ equity increased to $15.2 million, while accumulated deficit reached $189.8 million. The company’s common stock now trades on the OTCQB Venture Market under the symbol RVPH.
Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of 1,072,690 shares of Reviva Pharmaceuticals Holdings, Inc. common stock on this Amendment No. 1 to Schedule 13G. This position represents 8.2% of the outstanding class.
The reporting persons have shared voting and dispositive power over all 1,072,690 shares and no sole voting or dispositive power. The shares are held by entities subject to voting control and investment discretion of Millennium Management LLC and related managers, and the filing states that this structure should not, by itself, be construed as an admission of beneficial ownership. The parties also enter into a Joint Filing Agreement dated July 31, 2026.
UBS Group AG, together with its wholly owned subsidiaries UBS Financial Services Inc. and UBS Securities LLC, reports that it no longer beneficially owns any shares of Reviva Pharmaceuticals Holdings, Inc. common stock, par value $0.0001 per share.
As of 06/30/2026, UBS Group discloses 0 shares beneficially owned, representing 0% of the class. It reports no sole or shared voting power and no sole or shared dispositive power over Reviva common stock, and indicates that it now holds 5 percent or less of the class.